What Novo Nordisk's disappointing trial results mean for the obesity drug market Novo Nordisk presents phase 3 data for next generation amylin cagrilintide, leading to advancement into dedicated clinical programme Novo Nordisk advances obesity candidate to late stage program after weight loss of less than 12% Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE 1 Trial? Seeking Alpha
Shopping security
Each payment you make on thelockerguy is secured with strict SSL encryption and PCI DSS data protection protocols